BiVictriX Therapeutics plc (AIM:BVX)

Market Cap	8.25M
Revenue (ttm)	n/a
Net Income (ttm)	-2.67M
Shares Out	82.53M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,774,830
Average Volume	1,101,011
Open	n/a
Previous Close	8.50
Day's Range	10.00 - 10.00
52-Week Range	10.00 - 14.00
Beta	n/a
RSI	59.32
Earnings Date	Sep 17, 2024

About BiVictriX Therapeutics

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 17
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BVX